Hancock
Regional Hospital

June 22, 2006

U.S. Nuclear Regulatory Commission
Region III
Materials Licensing Section
2443 Warrenville, RD
Lisle, IL 60532-4352

Dear Sir,

Please amend NRC License 13-16730-01 to reflect the following changes/additions.

1) Please remove John P. Jacobs, MD as an authorized user.

2) Please add Gladys Irene Minor, MD as an authorized user with the same privileges granted on license number 13-32241-01, Amendment number, 8.

A copy of this license is enclosed.

Sincerely,

Lisa Wood

Lisa Wood
Team Leader Diagnostic Imaging Services/Cardiovascular Services

LW:baw

Encl.

801 North State St.
Greenfield, IN 46140

Phone (317) 462-5544

NRC FORM 374 U.S. NUCLEAR REGULATORY COMMISSION PAGE 1 OF 5 PAGES
Amendment No. 08

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

Licensee	**In accordance with the letters dated March 19, 2004, and May 10, 2004,**
1. Central Indiana Cancer Centers	3. License number 13-32241-01 is amended in Its entirety to read as follows:
2. 1346 East County Line Road Indianapolis, IN 46227	4. Expiration date July 31, 2010
	5. Docket No. 030-35383 Reference No.

6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license
A. Any byproduct material permitted by 10 CFR 35.100	Any	A. As needed
B. Any byproduct material permitted by 10 CFR 35.200		B. As needed
C. Any byproduct material permitted by 10 CFR 35.300		C. As needed, not to exceed two curies of Iodine-131
D. Iodine-125, as permitted by 10 CFR 35.400	Sealed sources as seeds	D. As needed
E. Palladium-103, as permitted by 10 CFR 35.400	E. Sealed sources as seeds	E. As needed
F. Iridium-192 as permitted by 10 CFR 35.600	F. Sealed sources (Nucletron Model No. 105.002, manufactured by Mallinckrodt Medical BV or AEA Technology, Inc.)	**F. Two sources not to exceed 12 curies**
G. Cesium-137	G. Sealed source (Tech-Ops Model No. 77302)	G. One source not to exceed 165 millicuries
H. Iodine-125, as permitted by 10 CFR 35.1000	H. Liquid as Iotrex™	H. 8.0 curies

9. Authorized Use:

A. Medical use permitted by 10 CFR 35.100.

B. Medical use permitted by 10 CFR 35.200.

NRC FORM 374A U.S. NUCLEAR REGULATORY COMMISSION	PAGE 2 of 5 PAGES
MATERIALS LICENSE **SUPPLEMENTARY SHEET**	License Number 13-32241-01
	Docket or Reference Number 030-35383
	Amendment No. 08

C. Medical use permitted by 10 CFR 35.300.

D. and E. Medical use permitted by 10 CFR 35.400 for which the patient can be released pursuant to 10 CFR 35.75.

F. One source for medical use, as permitted by 10 CFR 35.600, in a Nucletron Corporation Model No. 105.999 MicroSelectron HDR remote afterloading brachytherapy device. One source in its shipping container for source replacement.

G. For use in a Technical Operations/Nuclear Associates Model 773 Gamma survey instrument calibrator for the calibration of the licensee's own survey instruments.

H. For medical use permitted by 10 CFR 35.1000, in the Proxima Therapeutics' GliaSite® Radiotherapy System.

CONDITIONS

10. A. Licensed material in Subitem Nos. 6.D., 6.E., 6.F., and 6.H. shall be used at the licensee's facilities located at the Radiation Therapy Department, 8 East County Line Road, Indianapolis, Indiana.

B. Licensed material in Subitem Nos. 6.F. and 6.H. shall be used at the licensee's facilities located at the Radiation Therapy Department, 1[illegible] Suite #50, Greenfield, Indiana.

C. Licensed material in Subitem Nos. 6.F. and 6.H. shall be used at the licensee's facilities located at The Radiation Therapy Department, 10212 Lantern Road, Fishers, Indiana.

D. Licensed material in Subitem Nos. 6.A., 6.B., 6.C., 6.F. and 6.H. shall be used at the licensee's facilities located at The Radiation Therapy Department, 6845 Rama Drive, Indianapolis, IN.

E. The licensed material in Subitem No. 6.F., may be transported between the four locations of use in Condition Nos. 10.A.,10.B., 10.C., and 10.D., in accordance with the statements, commitments and representations made in the application dated February 16, 2000, and the letters dated February 17, 2000, May 2, 2000, June 26, 2000, January 29, 2003, April 9, 2003, May 27, 2003, and the facsimile dated May 5, 2003.

11. A. The Radiation Safety Officer for this license is Yun Wang, Ph.D.

B. The Alternate Radiation Safety Officer for this license is Morgan E. Tharp II, M.D.

12. Licensed material is only authorized for use by, or under the supervision of:

A. Individuals permitted to work as an authorized user, and/or authorized medical physicist in accordance with 10 CFR 35.13 and 35.14.

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License Number
13-32241-01

Docket or Reference Number
030-35383

Amendment No. 08

B. The following individuals are authorized users for medical uses:

Authorized Users	Material and Use
Nini Bermudez, M.D.	Iodine-125 and palladium-103 (as permitted by 10 CFR 35.400) and 35.600.
John Paul Jacobs, M.D.	10 CFR 35.300, iodine-125 and palladium-103 (as permitted by 10 CFR 35.400) and 35.600.
Morgan E. Tharp II, M.D.	10 CFR 35.300, iodine-125 and palladium-103 (as permitted by 10 CFR 35.400), 35.600 and iodine-125 in the Proxima Therapeutics' GliaSite® Radiotherapy System.
Michael C. Hardacre, [illegible]	Iodine-125 and [illegible]ium-103 (as permitted by 10 CFR 35.400) [illegible].600.
Gladys Irene Minor, M.D.	10 CFR 35.[illegible]cluding treatment of h[illegible]yroid[illegible]odine-125 (as permitted by 10 [illegible]35.600.
David Kurlander, M.D.	10 CFR [illegible].400 a[illegible].200.

C. The following individual is an authorized user for medical uses:

Authorized User	Material and Use
Yun Wang, Ph.D.	Cesium-137 survey instrument calibration.

D. The following individual is an Authorized Medical Physicist:

Yun Wang, Ph.D.	Iridium-192 in High Dose Rate Remote Afterloading Brachytherapy device, palladium-103 and iodine-125 as permitted by 10 CFR 35.400, iodine-125 in the Proxima Therapeutics' GliaSite® Radiotherapy System and for calibrations, spot checks and training.

13. The licensee may use byproduct material listed in Subitem 6.F. for mobile HDR remote afterloading brachytherapy services as described in the application dated February 16, 2000, (excluding all reference to the radiation survey report for the Varian 2100C, S/N 1268 linear accelerator dated August 14, 1998), and the letters dated February 17, 2000 (excluding Attachment #2), May 2, 2000 (excluding attached Quality Management Program), June 26, 2000, and August 8, 2000, September 15, 2000, February 6, 2001 (excluding references to survey report and HDR prostate implant journal article), February 6, 2001, and March 1, 2001.

NRC FORM 374A U.S. NUCLEAR REGULATORY COMMISSION	PAGE 4 of 5 PAGES
MATERIALS LICENSE **SUPPLEMENTARY SHEET**	License Number 13-32241-01 Docket or Reference Number 030-35383 Amendment No. 08

14. For sealed sources not associated with 10 CFR Part 35 use, the following conditions apply:

A. Sealed sources shall be tested for leakage and/or contamination at intervals not to exceed 6 months or at such other intervals as specified by the certificate of registration referred to in 10 CFR 32.210.

B. In the absence of a certificate from a transferor indicating that a leak test has been made within 6 months prior to the transfer, a sealed source or detector cell received from another person shall not be put into use until tested.

C. Sealed sources need not be leak tested if:

(i) they contain not more than 100 microcuries of beta and/or gamma emitting material;

(ii) they are not designed to emit alpha particles, are in storage, and are not being used. However, when they are removed from storage for use or transferred to another person, and have not been tested within the required leak test interval, they shall be tested before use or transfer. No sealed source or detector cell shall be stored for a period of more than 10 years without being tested for leakage and/or contamination.

(iii) the half-life of the isotope [illegible]

(iv) they contain not more [illegible] beta and/or gamma emitting material or not more than 10 microcuries of [illegible] emitting material;

(v) they are not designed to emit alpha [illegible] are in storage, and are not being used. However, when they are removed from storage [illegible] or transferred to another person, and have not been tested within the required leak test interval, they shall be tested before use or transfer. No sealed source or detector cell shall be stored for a period of more than 10 years without being tested for leakage and/or contamination.

D. The leak test shall be capable of detecting the presence of 0.005 microcurie (185 becquerels) of radioactive material on the test sample. If the test reveals the presence of 0.005 microcurie (185 becquerels) or more of removable contamination, a report shall be filed with the U.S. Nuclear Regulatory Commission in accordance with 10 CFR 30.50(c)(2), and the source shall be removed immediately from service and decontaminated, repaired, or disposed of in accordance with Commission regulations.

E. Tests for leakage and/or contamination shall be performed by the licensee or by other persons specifically licensed by the Commission or an Agreement State to perform such services.

15. The licensee is authorized to transport licensed material in accordance with the provisions of 10 CFR Part 71, "Packaging and Transportation of Radioactive Material."

16. Sealed sources containing licensed material shall not be opened or sources removed from source holders by the licensee.

NRC FORM 374A U.S. NUCLEAR REGULATORY COMMISSION PAGE 5 of 5 PAGES

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License Number
13-32241-01

Docket or Reference Number
030-35383

Amendment No. 08

17. For material in SubItem No. 6.E., the licensee shall conduct a physical inventory every 6 months to account for all sources and/or devices received and possessed under the license. Records of inventories shall be maintained for 5 years from the date of each inventory.

18. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.

A. The application dated February 16, 2000, (excluding all reference to the radiation survey report for the Varian 2100C, S/N 1268 linear accelerator dated August [illegible] 1998); and,

B. The letters dated February 17, [illegible] (excluding Attachment 2), May 2, 2000 (excluding attached Quality Management Program), [illegible], August [illegible], 2000, September 15, 2000, February 5, 2001 (excluding references to [illegible] report and HDR [illegible] implant journal article), February 6, 2001, March 1, 2001, January [illegible], 2003, March 10, 2004, **March 19, 2004, and May 10, 2004;**

C. The facsimiles dated May 5, [illegible], May [illegible], 2004, and May [illegible], 2004.

FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Date JUL 2 9 2004

By Colleen Carol Casey
Colleen Carol Casey
Materials Licensing Branch
Region III

Hancock®
Regional Hospital

DIS
801 North State St.
Greenfield, IN 46140

BETTER HEALTH IS RIGHT HERE

Hasler

016H26504494
$00.63⁰
06/23/2006
Mailed From 46140
US POSTAGE

U.S. Nuclear Regulatory Commission
Region III
Materials Licensing Section
2443 Warrenville, RD
Lisle, IL 60532-4352

60532+3673-99 C021